Search Results for "A-200"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for A-200. Results 631 to 640 of 653 total matches.

Who Should Take Vitamin Supplements?

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2011  (Issue 1379)
-analysis of 30 trials involving 11,350 subjects showed that prophylactic use of >200 mg/day of vitamin C ...
Many patients ask their healthcare providers whether they should take vitamins. Since the last Medical Letter article on this subject, more data have become available on the benefits and risks of taking vitamins.
Med Lett Drugs Ther. 2011 Dec 12;53(1379):101-3 |  Show IntroductionHide Introduction

Daridorexant (Quviviq) for Insomnia

   
The Medical Letter on Drugs and Therapeutics • Jul 11, 2022  (Issue 1654)
106.0 -24.2* -24.3* Placebo 71.8 -20.0 -19.9 108.1 -12.6 -14.0 * Statistically significant difference ...
The FDA has approved daridorexant (Quviviq – Idorsia), an orexin receptor antagonist, for treatment of sleep-onset and/or sleep-maintenance insomnia in adults. Daridorexant is the third orexin receptor antagonist to be approved for this indication; suvorexant (Belsomra) and lemborexant (Dayvigo) were approved earlier.
Med Lett Drugs Ther. 2022 Jul 11;64(1654):107-10 |  Show IntroductionHide Introduction

Suflave — A Low-Volume Colonoscopy Preparation

   
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023  (Issue 1685)
24.90 23.70 39.10 Low-Volume PEG 3350-Based MoviPrep (Salix)9 generic 200 g PEG 3350 powder10 240 ...
The FDA has approved Suflave (Sebela/Braintree), a low-volume polyethylene glycol (PEG)- and sulfate-based product for cleansing of the colon prior to colonoscopy in adults. Other oral colonoscopy preparations available in the US are listed in Table 2. Suflave is marketed as tasting better than other products.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):148-51   doi:10.58347/tml.2023.1685b |  Show IntroductionHide Introduction

Drugs for Percutaneous Coronary Interventions

   
The Medical Letter on Drugs and Therapeutics • Dec 06, 2004  (Issue 1197)
to ACT 250-300 sec 2 (50-70 post-PCI units/kg IV if GP IIb/IIIa used, titrate to ACT 200-250 sec ...
Percutaneous coronary intervention (PCI), such as balloon angioplasty or stent placement, predisposes to subsequent thrombosis. The current pharmacologic approach to prevention of this problem combines an anticoagulant with one or more antiplatelet drugs.
Med Lett Drugs Ther. 2004 Dec 6;46(1197):100 |  Show IntroductionHide Introduction

Vaccines for Travelers

   
The Medical Letter on Drugs and Therapeutics • Nov 19, 2018  (Issue 1560)
, and those with asymptomatic HIV infection and moderate immune suppression (CD4 counts 200-499 cells/mm3 ...
Persons planning to travel outside the US should be up to date on routine vaccines and, depending on their destination, duration of travel, and planned activities, may also receive certain travel-specific vaccines. Tickborne encephalitis and dengue vaccines, which are not available in the US, are reviewed in a separate article available online. Detailed advice for travel to specific destinations is available from the Centers for Disease Control and Prevention (CDC) at www.cdc.gov/travel/destinations/list. Recommendations for administration of vaccines as part of routine...
Med Lett Drugs Ther. 2018 Nov 19;60(1560):185-92 |  Show IntroductionHide Introduction

Drugs for ADHD

   
The Medical Letter on Drugs and Therapeutics • Jan 27, 2020  (Issue 1590)
or bid32/40 mg See footnote 15 200.30 divided bid Evekeo ODT 5, 10, 15, 20 mg ODT14 10 h31 5 mg qAM ...
Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder that has been diagnosed in up to 10% of school-age children in the US and frequently persists into adulthood. A study in a large Danish cohort found that ADHD was associated with higher mortality rates in children, adolescents, and adults, mainly due to accidents. Pharmacologic treatment of ADHD in children has been reported to decrease the risk of substance abuse in adolescents, and use of ADHD medications in adults has been associated with a reduced risk of serious traffic accidents and...
Med Lett Drugs Ther. 2020 Jan 27;62(1590):9-15 |  Show IntroductionHide Introduction

Drugs for Treatment and Prevention of Venous Thromboembolism

   
The Medical Letter on Drugs and Therapeutics • Jul 25, 2022  (Issue 1655)
units SC q8-12h $651.00 Low-Molecular-Weight Heparins (LMWHs) Dalteparin – Fragmin (Pfizer) 200 IU/kg ...
Anticoagulants are the drugs of choice for treatment and prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE). US guidelines for treatment of VTE were updated in 2020 and 2021.
Med Lett Drugs Ther. 2022 Jul 25;64(1655):113-20 |  Show IntroductionHide Introduction

Lipid-Lowering Drugs

   
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022  (Issue 1659)
, 200 mg caps 200 mg PO once/day24 24.00 Antara27 (Lupin) 30, 90 mg caps 90 mg PO once/day 507.90 ...
Cholesterol management guidelines from the American College of Cardiology/American Heart Association Task Force were last published in 2019.
Med Lett Drugs Ther. 2022 Sep 19;64(1659):145-52 |  Show IntroductionHide Introduction

Varenicline (Chantix) for Tobacco Dependence

   
The Medical Letter on Drugs and Therapeutics • Aug 14, 2006  (Issue 1241)
, hyperanxiety state, Stevens-Johnson syndrome (rare) sustained release – generic 100, 150 and 200 mg tabs ...
Varenicline tartrate (Chantix - Pfizer) is now available for oral treatment of tobacco dependence. Some other drugs for this indication are listed in this article.
Med Lett Drugs Ther. 2006 Aug 14;48(1241):66-8 |  Show IntroductionHide Introduction

Intravenous Immunoglobulin (IVIG)

   
The Medical Letter on Drugs and Therapeutics • Dec 04, 2006  (Issue 1249)
vials PID 200 mg/kg/mo (Baxter) Kawasaki syndrome 2 g/kg over 10 hrs once or 400 mg/kg x 4d 2 ...
Intravenous immunoglobulin (IVIG) has 6 FDA approved indications and is prescribed off-label for many others. How many of these uses are justified is controversial.
Med Lett Drugs Ther. 2006 Dec 4;48(1249):101-2 |  Show IntroductionHide Introduction